Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proteasome subunit beta type-5 (PSMB5) is a catalytic subunit of the 20S core proteasome complex, essential for intracellular protein degradation. It possesses chymotrypsin-like activity, cleaving peptide bonds after hydrophobic amino acid residues. PSMB5 plays a crucial role in maintaining cellular protein homeostasis and is implicated in various diseases, including cancer, neurodegeneration, and autoimmune disorders. It is a validated drug target, with inhibitors like bortezomib and carfilzomib used in multiple myeloma treatment. Drug resistance can arise from mutations or overexpression of PSMB5.
Inhibition of chymotrypsin-like activity of the proteasome
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteasome Subunit Beta Type-5 (PSMB5).